0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > VEGF165 > GMP-VE5H23

GMP Human VEGF165 Protein

Recommended Hot Products:
PG version VE5-H4210 is now available for seamless transition.

Order Now

  • Features
    1. Designed under ISO 9001:2015 and ISO 13485:2016

    2. Manufactured and QC tested under a GMP compliance factory

    3. Animal-Free materials

    4. Beta-lactam materials free

    5. Batch-to-batch consistency

    6. Stringent quality control tests

  • Source
    GMP Human VEGF165 Protein(GMP-VE5H23) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
    Predicted N-terminus: Ala 27
  • Molecular Characterization
    VEGF165 Structure

    This protein carries no "tag".

    The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 10 EU/mg by the LAL method.
  • Host Cell Protein
    <0.5 ng/µg of protein tested by ELISA.
  • Host Cell DNA
    <0.02 ng/μg of protein tested by qPCR.
  • Sterility
    The sterility testing was performed by membrane filtration method described in CP<1101>, USP<71> and Eur. Ph. 2.6.1.
  • Mycoplasma
    Negative.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with protectants.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • Storage

    Upon receipt, store it immediately at -20°C or lower for long term storage.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 5 years in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
SDS-PAGE
VEGF165 SDS-PAGE

GMP Human VEGF165 Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

Bioactivity-Bioactivity CELL BASE
 VEGF165 CELL

GMP Human VEGF165 Protein (Cat. No. GMP-VE5H23) stimulates proliferation of 293F-NFAT/Luc-VEGFR2-3-7 cells. The specific activity of GMP Human VEGF165 Protein is>8.00 X 10^5 IU/mg, which is calibrated against human vascular endothelial growth factor 165 WHO International Standard (NIBSC code: 02/286) (QC tested).

 VEGF165 CELL

The activity of GMP Human VEGF165 Protein (Cat. No. GMP-VE5H23) was higher than other competing products.

Application Data
 VEGF165 APPLICATION DATA

GMP Human SCF Protein (Cat. No. GMP-SCFH25), GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25), GMP Human Flt-3 Ligand Protein (Cat. No. GMP-FLLH28), GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) and GMP Human VEGF165 Protein (Cat. No. GMP-VE5H23) could significantly promote the iPSC differentiation to HSPCSs after 14 days, highly expressed hematopoietic stem cell markers CD34 and CD45.

Bioactivity-Stability
 VEGF165 STABILITY

The Cell based assay shows that GMP Human VEGF165 Protein (Cat. No. GMP-VE5H23) is stable at 37°C for 24 hours.

 VEGF165 STABILITY

The Cell based assay shows that GMP Human VEGF165 Protein (Cat. No. GMP-VE5H23) is stable after freezing and thawing 3 times.

 VEGF165 STABILITY

The Cell based assay shows that GMP Human VEGF165 Protein (Cat. No. GMP-VE5H23) is stable at 4℃ for 180 days.

 VEGF165 STABILITY

The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG VEGF165.

  • MANUFACTURING SPECIFICATIONS

    ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.


    ACROBiosystems Quality Management System Contents:

    1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory.

    2. Animal-Free materials

    3. Materials purchased from the approved suppliers by QA

    4. ISO 5 clean rooms and automatic filling equipment

    5. Qualified personnel

    6. Quality-related documents review and approve by QA

    7. Fully batch production and control records

    8. Equipment maintenance and calibration

    9. Validation of analytical procedures

    10. Stability studies conducted

    11. Comprehensive regulatory support files

    Request For Regulatory Support Files(RSF)


    ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

    1. SDS-PAGE

    2. Protein content

    3. Endotoxin level

    4. Residual Host Cell DNA content

    5. Residual Host Cell Protein content

    6. Biological activity analysis

    7. Microbial testing

    8. Mycoplasma testing

    9. In vitro virus assay

    10. Residual moisture
    11. Batch-to-batch consistency

  • Background
    VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €480.00

Price(EUR) : €2530.00

Price(EUR) : €3540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:40 Details
  • Number of Drugs in Clinical Trials:63 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message